3 terminated, 2 completed. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 3, Completed 2 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Elan Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis ELND002 - Multiple Sclerosis | Phase 1 | Terminated | Elan Pharmaceuticals | 12 | 2010-12-01 | 2015-12-14 |
| A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis ELND002, Placebo - Multiple Sclerosis | Phase 1 | Terminated | Elan Pharmaceuticals | 32 | 2010-03-01 | 2015-12-14 |
| Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) mefloquine - Progressive Multifocal Leukoencephalopathy | Phase 1 / Phase 2 | Terminated | Biogen | 37 | 2009-01-01 | 2014-07-31 |
| Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) natalizumab, standard of care - Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 1 | Completed | Biogen | 76 | 2007-10-01 | 2014-09-09 |
| "DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?" Botulinum Toxin type B - Cerebral Palsy | Phase 1 / Phase 2 | Completed | Stanford University | 10 | 2002-01-01 | 2005-10-13 |
Multiple Sclerosis (3) · Multiple Sclerosis, Relapsing-Remitting (2) · Central Nervous System Diseases (1) · Cerebral Palsy (1) · Leukoencephalopathy, Progressive Multifocal (1) · Multiple Sclerosis, Chronic Progressive (1)
Mefloquine (1) · Natalizumab (1) · Standard of Care (1) · rimabotulinumtoxinB (1)
United States (4) · Brazil (1) · Canada (1) · Germany (1) · Italy (1) · Spain (1)